I n t r o d u c t i o n
Chronic facial pain is most often caused by a myoathropathy (MAP) of the masticatory system in particular by a myogeneous form. In a minority of 10-15% of the patients, the facial pain is associated to high pain-related disability and high rates of psychosocial distress so that these patients are to be considered as chronic pain patients (Von Korff et al., 1988 ,Dworkin and Massoth, 1994 ,Palla, 2006 .
Although the exact underlying pathophysiology of chronic myogeneous facial pain is poorly understood, there is growing evidence for a multifactorial etiology (Suvinen et al., 2005) .
Many patients report stressful life-events at the onset or during their painful state (Aghabeigi et al., 1992) and there is a substantial overlap between a chronic myoarthropatic pain and other stress related (Korszun et al., 1998) . A physiological substrate of stress is constituted by dysregulations of the hypothalamus-pituitary-adrenal (HPA) axis, which have been observed in patients with chronic pain and fatigue disorders such as chronic fatigue syndrome and fibromyalgia (Parker et al., 2001 ), whiplash-associated disorder (Gaab et al., 2005) , chronic pelvic pain (Heim et al., 1998) , low back pain (Griep et al., 1998) , irritable bowel syndrome as well as in persons exposed to chronic or traumatic stress (Yehuda et al., 1993,Meinlschmidt and Heim, 2005) . In patients with these chronic pain and fatigue symptoms as well as in the traumatized persons reduced activity and / or enhanced negative feedback sensitivity of the HPA-axis was found. In other terms for patients with these chronic somatic symptoms there is accumulating evidence of a basal hypocortisolism and an altered cortisol response to stress challenge (Parker et al.,
2001; Tanriverdi et al., 2006).
The low dose (0.5 mg) dexamethasone suppression test (DST) selectively assesses the negative feedback sensitivity of the HPA axis on the level of the pituitary gland (Yehuda et al., 1993) .
Dexamethasone mainly suppresses HPA-axis functioning via hypophyseal pathways since it does not readily cross the blood-brain-barrier (De Kloet, 1997) . The low dose DST has been shown to be of diagnostic value in depression, post traumatic stress disorders, chronic pain and fatigue syndromes (Hunt et al., 1991 ,Yehuda et al., 1993 ,Heim et al., 1998 , (Gaab et al., 2002 ,Gaab et al., 2005 . Up to date only a few studies investigated the role of HPA hormones in MAP patients under natural (Korszun et al., 2002) and experimental conditions (Jones et al., 1997 ,Yoshihara et al., 2005 . The aim of this study was therefore to perform the DST in patients with chronic myogeneous facial pain, the hypothesis being that this group of patients has a dysregulation of the HPA axis compared to healthy controls. This could help to clarify the etiology of chronic myogeneous facial pain.
Me t h o d s

S u b j e c t s
20 patients (3 men, 17 female, mean age 35.2) with chronic myogeneous facial pain, recruited from a population of patients seeking treatment at the orofacial pain clinic were included in the patient group. 20 controls (3 men, 17 female, mean age 37.0) were selected from a pool of healthy, pain-free subjects recruited from an unselected general population and that had been used as controls also in a previous study (Gaab et al., 2002 ,Gaab et al., 2005 . None of the controls had reported facial pain in the preceding 6 months and never had received treatment for a MAP. These controls were matched by age, gender and body mass index (BMI). All subjects filled out a written informed consent form. The study was approved by the Ethical Committee of the Medical Council of the Canton of Zurich. The recruitment of the myogeneous pain patients consisted of two consecutive steps: First, patients with a diagnosis of myoarthropathic pain were informed about the study goal. Interested subjects in the age range 18-60 years, fluent in German language and with facial pain were scheduled for a clinical examination by three reliable, calibrated dentists in order to select patients with myogeneous facial pain according to the the RDC/TMD (Dworkin and LeResche, 1992), i . e . (1) a report of pain in the jaw, temples, face, preauricular area, or inside the ear at rest or during function and (2) tenderness to palpation of three or more of the 14 examined muscle sites (see below), with at least one tender point on the painful side. At least two of the three diagnoses had to coincide. The presence of TMJ arthralgia and of a painless disc displacement with reduction did not lead to exclusion.
Exclusion criteria for all study participants including the controls were: A diagnosis of functional somatic disorders, pregnancy, lactation, drug addiction, acute injuries as well as inhalative or systemic treatment with glucocorticoids that were addressed by means of an interview and a check-list. Further exclusion criteria were a current psychiatric diagnosis of a major psychiatric disorder (psychotic disorder, bipolar disorder, major depressive disorders, anxiety disorders, post-traumatic stress disorder, eating disorder, suicidality), use of antidepressants, anxiolytic, antibiotic, antihypertensive or steroid medication. These exclusion criteria were chosen in order to control for possible main effects of psychiatric disorders and medication on dependent variables. Occasional medication of NSAIDs was accepted (and reported by 3 patients) as NSAIDs did't alter the cortisol response on experimentally induced stress (Kudielka et al., 2008) .
C l i n i c a l e x a mi n a t i o n
The clinical examination, which was performed only on patients, followed the protocol described in the RDC/TMD (Dworkin and LeResche, 1992) . The clinical examination included measurement of active and passive maximum opening, of active protrusion and laterotrusion, palpation and auscultation of the TMJ area and palpation of masticatory muscles. In contrast to the RDC criteria, only seven muscle sites per side were examined, i.e. the anterior, medial and posterior portion of the temporal muscle, the insertions of the temporal and medial pterygoid muscles, the superficial and deep 
P s y c h o l o g i c a l e v a l u a t i o n
All patients and controls were screened for psychiatric disorders using a short screening questionnaire (Wittchen and Pfister, 1997) and interviewed by clinical psychologists (JG or UG) to ensure the absence of exclusion criteria (vide supra) for participating in the study. All subjects completed a battery of questionnaires, including the German version of the Hospital Anxiety and Depression ScaleGerman Version (HADS-D, (Zigmond and Snaith, 1983) , the Fatigue Scale (FS, (Chalder et al., 1993) , and visual analogue scales (VAS; 0 = no pain, 100 = worst pain imaginable) to assess pain, sleep duration and sleep quality before, during, and after sampling days.
C o r t i s o l a s s e s s me n t a n d b i o c h e mi c a l a n a l y s i s
In order to assess the salivary free cortisol level saliva was collected at home by means of Salivettes (Sarstedt, Rommelsdorf, Germany). Subjects had to chew on a cotton salivette during a 1-min period according to the manufacturer's instructions. They had to collect samples on two consecutive days, allowing the assessment of the variation of the cortisol levels after awakening (cortisol awakening response) and over the day (short circadian cortisol profile).
For the assessment of the cortisol awakening response samples were obtained immediately after awakening and 15, 30, 45 and 60 min thereafter. The subjects had to remain lying in bed for the first 15 min. and not to have breakfast or brush the teeth during the first hour after awakening in order to avoid false high cortisol values due to plasma exudates from minor bleeding in the oral cavity. For the measurement of the short circadian cortisol profile four additional saliva samples were collected at 8.00, 11.00, 16.00 and 20.00 o'clock. However, as subjects were free to wake up according to their normal schedule, the collection time for the first sample could vary individually. Subjects were asked not to eat or drink for 30 min before taking these four samples. In conclusion, each subject collected 18 samples, 9 per day.
In order to assess a possible dysregulation of the HPA axis subjects and patients took an oral dose of 0,5 mg dexamethasone (Merck, Germany) at 11.00 p.m. on the first day.
The saliva samples were stored in the refrigerator until completion of sampling and then brought to our laboratory where they were stored at -20°C until biochemical analysis took place. The salivary free cortisol was analyzed by using commercial chemiluminescence immunoassay (IBL, Hamburg, Germany). Inter-and intraassay coefficients of variation were below 10%. To reduce error variance caused by imprecision of the intraassay, all samples of one subject were analyzed in the same run.
Collection and return of saliva sample as well as compliance with the protocol were supervised by study personnel.
In order to calculate the sleep duration subjects had to record bed and awakening times.
S t a t i s t i c a l a n a l y s i s
Kolmogorov-Smirnov tests showed that salivary free cortisol data were not normally distributed.
Calculating the log of cortisol values produced nearly normally distributed values so that Logtransformed cortisol values were used in order to perform parametric statistical tests. However, the results present means and standard deviations of the untransformed values. Data were also tested for homogeneity of variance using Levene´s test before statistical procedures were applied.
ANOVAs for repeated measures were computed to analyze cortisol data, with clinical diagnosis as a grouping variable and time as the repeated measures factor. All reported results were corrected by the Greenhouse-Geisser procedure when assumptions of sphericity were violated. Correlations were computed by Pearson product-moment correlation. Possible differences in the psychological scores between the two groups were analyzed by Student's t-test, ANOVA or MANOVA.
For salivary cortisol levels after awakening, the areas under the curve with respect to ground (AUCg) 
Re s u l t s
All patients fulfilled the criteria for a diagnosis of myogeneous facial pain according to the RDC/TMD (Dworkin and LeResche, 1992 The mean pain duration was 71 months and the median was 48 months, with a range of 6 to 420 months. With the exclusion of the only patient with a pain duration of 420 months the group mean pain duration was 52 months, with a range of 6-120 months.
Symptoms duration was not associated with any psychometric scores or cortisol levels (pain duration-HADS anxiety: r=0.12; -HADS depression: r=-0.28; -physical fatigue: r=-0.18: -mental fatigue: r=-0.23, -AUCg day 1: r=-0.41; -AUCg day 2: r=-0.01; -mean cortisol levels day 1: r=0.002 -mean cortisol levels day 2: r=-0.04; all n.s.).
C o r t i s o l l e v e l s
Da y 1 . The salivary free cortisol levels increased significantly in both groups after awakening (time effect: F 2.4, 87.7 =10.5, p<0.001), the differences between the two groups being statistically not significant (group by time effect: F 2.4, 87.7 =0.6, p=0.59, Figure 1 ). The cortisol levels significantly changed over the course of day 1 (time effect: F .2.5, 93.9 =34.4, p<0.000), but cortisol levels over the short circadian profile did not differ between myogeneous pain patients and controls (group by time effect: F 2.5, 93.9 =1.6, p=0.21, Figure 2 ).
Da y 2 .
In both groups the cortisol levels did neither increase significantly after awakening nor change during the day (time effects: F 1.7, 62.4 =0.4, p=0.71 and F 1.6, 58.3 =1.2, p=0.30, respectively). Due to the lack of significant changes over time, group effects rather than group by time effects were calculated.
In both groups the intake of 0.5 mg of dexamethasone lead to a significant decrease in the cortisol levels both during the awakening response as well as the short circadian profile ( Fig. 1 and 2) .
However, the decrease in the myogeneous pain patients group was statistically significantly larger than in the control group (group effects: awakening cortisol levels F 1, 37 =4.3, p=0.04, Fig. 1 Figure 3 ).
C o mp l i a n c e t o p r o t o c o l : All 20 myogeneous pain patients confirmed having taken dexamethasone.
This is confirmed by the results as, in all subjects, an at least 50% reduction of the individual awakening AUCg and mean circadian cortisol levels on day 2 in comparison to day 1 was observed.
The compliance was further confirmed by a second order interaction between cortisol measures x group x assessment day, with a significant interaction effect for awakening salivary cortisol (F 2.5, 91.7 =9.6, p<0.000) and for the short circadian cortisol profile (F 2.5, 91.7 =21.2, p<0.000).
As described above, all participants were informed in detail about the importance of adherence to the protocol. However we did not used any specific method or instrument for directly controlling sample time, i.e. electronic monitor caps or palm-pilots (Kudielka et al. Psychosomatic Med, 2003) .
P s y c h o me t r i c a n d s l e e p v a r i a b l e s :
Myogeneous pain patients exhibited significantly higher scores on depression, anxiety, physical fatigue and mental fatigue. However, depression scores remained below the cut-off score for clinical relevance , whereas anxiety levels were above. (Table 1 ). Also, myogeneous pain patients exhibited a lower quality of sleep than controls on both assessment days (Table 1) Before intervention, all cortisol levels were inconspicuous in our sample. This finding contrasts to the report by Korszun and colleagues (Korszun et al., 2002) , who found significant higher basal circadian cortisol levels in temporomandibular disorders (TMD) patients compared to controls. However, methodological differences between the studies need to be noted. The TMD patients examined by Korszun et al. (2002) had low pain intensity, and high depression scores. Our myogeneous facial pain patients group on the other hand was characterized by a moderate to high mean pain intensity level, but low mean depression score. The reported cortisol differences between their study and our study may be due to these differences, since the awakening cortisol responses are sensitive to the individual symptomatic profile . Two studies investigated the HPA axis reactivity of TMD patients to experimentally induced psychosocial stress. One reported an elevated cortisol response to a standardized stress paradigm in a subgroup of TMD patients compared to controls (Jones et al., 1997).
These results were partly confirmed by a recent study, reporting higher cortisol stress responses in patients with myofacial pain in comparison to healthy controls (Yoshihara et al., 2005) . However, it needs to be noted that these two studies examined cortisol responses to experimental induced stress in contrast to our approach that observed cortisol levels upon awakening and across the circadian rhythm.
The different findings could thus be due to disparate underlying neuroendocrine processes (Herman and Cullinan, 1997). There is evidence for generalized hyperalgesia in MAP patients and hormonal as well as neural mechanisms leading to hyperexcitability and amplification of the nociceptive inputs have been discussed (Sarlani and Greenspan, 2003) . One possible mechanism leading to enhanced pain sensitivity may be a reduced release of corticotropin-releasing-hormone (CRH), since CRH seems to be involved in central as well as peripheral pain processing (Lariviere and Melzack, 2000) .
Interestingly the first human study on the CRH analgesic properties was done in dentistry: intravenous CRH administration lead to significantly less postoperative dental pain than with placebo (Hargreaves et al., 1987) . However, this study did not assess CRH or other directly associated hormones, such as adrenocorticotropin hormone (ACTH).
Some methodological shortcomings must be acknowledged. First: Previous studies has shown that objective compliance with protocol is lower than self-reported compliance especially when sampling period is over several days producing incorrect data particularly in the last sampling days. (Broderick JE, PNEC, 2003) . As we did not use electronic monitor caps or palm-pilots, compliance to protocol by the participants may be lower than expected. Although our study time was only two days and correct data collection more probable we strongly recommend these techniques in further studies.
Second: Dexamethasone bioavailability is considered to be important in interpreting cortisol suppression of dexamethasone. A study on depressed patients found a correlation between bioavailability of dexamethasone and cortisol suppression after dexamethasone intake, probably because of accelerated dexamethasone clearing. (Cassidy et al., 2000) . However, in several studies using the low-dose-dexamethasone-test, no different dexamethasone levels have been found in plasma or saliva nor was there a correlation between cortisol and dexamethasone levels (e.g. (Goenjian et al., 1996) . Dexamethasone bioavailability may be influenced by age and body-mass-index but as we matched our groups with respect to these factors, we consider that possible differences in dexamethasone bioavailability could explain our results.
In summary, the results showed that patients with chronic myogeneous facial pain have enhanced negative feedback sensitivity after the intake of a low dose of dexamethasone whereas the cortisol awakening response as well as the secretion of cortisol over the course of the day appear normal.
These results are in line with a multifactorial etiology of chronic facial pain.
This supports multidisciplinary treatment approaches for patients with chronic myogeneous facial pain similar to those used in other chronic pain disorders, including interventions for pain-and stressmanagement. 
